Serina Therapeutics, Inc. (SER)

ASE – Цена в реальном времени. Валюта: USD

1.81

-0.01 (-0.55%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.73

-0.08 (-4.42%)

После закрытия: Jun 26, 2026, 7:56 PM EDT

14.05.2026

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 -

07.04.2026

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for the delivery of a multitude of oligonucleotide payloads – HUNTSVILLE, AL, April 07, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Serina Therapeutics Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 5th LNP Formulation & Process Development Summit in Boston, MA. Entitled "Novel Lipid Nanoparticles Built Entirely on a POZ Platform", Dr. Moreadith will present data demonstrating the POZ-lipid in Serina's platform failed to elicit an antibody response to the polymer in a vaccine format in the rat.

02.04.2026

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported that the NYSE American LLC ("NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) or 1003(a)(ii) of the NYSE American Company Guide.

24.03.2026

Serina Therapeutics to Present at the 38th Annual Roth Conference

HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present in a fireside chat at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026, at 11:30 a.m. PST.

18.03.2026

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at $2.25 per share, representing a 68% premium to the March 17, 2026 closing price–

24.02.2026

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 –

19.02.2026

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

- First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1 - Company remains on track for first patient dosing in the first quarter of 2026

Видео

No Data

There is no data to display

Пресс-релизы

14.05.2026

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 -

02.04.2026

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

18.03.2026

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

24.02.2026

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 –

Serina Therapeutics, Inc. (SER)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Serina Therapeutics, Inc. (SER)

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics to Present at the 38th Annual Roth Conference

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Видео

No Data

Пресс-релизы

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics to Present at the 38th Annual Roth Conference

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Видео

No Data

Пресс-релизы

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Search stocks

Serina Therapeutics, Inc. (SER)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Serina Therapeutics, Inc. (SER)

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics to Present at the 38th Annual Roth Conference

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Видео

No Data

Пресс-релизы

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics to Present at the 38th Annual Roth Conference

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Видео

No Data

Пресс-релизы

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease